Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury
Pongpan Tanajak, Piangkwan Sa‐nguanmoo, Sivaporn Sivasinprasasn, et al.
Journal of Endocrinology (2017) Vol. 236, Iss. 2, pp. 69-84
Open Access | Times Cited: 111

Showing 1-25 of 111 citing articles:

Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction
Salva R. Yurista, Herman H.W. Silljé, Silke U. Oberdorf‐Maass, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 7, pp. 862-873
Open Access | Times Cited: 276
Mitochondrial quality control mechanisms as molecular targets in cardiac ischemia–reperfusion injury
Jin Wang, Hao Zhou
Acta Pharmaceutica Sinica B (2020) Vol. 10, Iss. 10, pp. 1866-1879
Open Access | Times Cited: 259
Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients
Laween Uthman, Antonius Baartscheer, Cees A. Schumacher, et al.
Frontiers in Physiology (2018) Vol. 9
Open Access | Times Cited: 169
The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
Hsiang‐Chun Lee, Yi-Lin Shiou, Shih‐Jie Jhuo, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 169
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Mohamad Arow, Maayan Waldman, Dor Yadin, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 164
Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury
Charshawn Lahnwong, Siripong Palee, Nattayaporn Apaijai, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 139
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry
Pasquale Paolisso, Luca Bergamaschi, Felice Gragnano, et al.
Pharmacological Research (2022) Vol. 187, pp. 106597-106597
Open Access | Times Cited: 88
Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning
Péter Ferdinandy, Ioanna Andreadou, Gary F. Baxter, et al.
Pharmacological Reviews (2022) Vol. 75, Iss. 1, pp. 159-216
Open Access | Times Cited: 87
SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways
Li Ma, Rongjun Zou, Wanting Shi, et al.
Theranostics (2022) Vol. 12, Iss. 11, pp. 5034-5050
Open Access | Times Cited: 82
Therapeutic strategies in ischemic cardiomyopathy: Focus on mitochondrial quality surveillance
Xing Chang, Sam Toan, Ruibin Li, et al.
EBioMedicine (2022) Vol. 84, pp. 104260-104260
Open Access | Times Cited: 79
Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms
Keming Huang, Xianling Luo, Bin Liao, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 46
Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Acute Coronary Syndrome: A Modern Cinderella?
Paschalis Karakasis, Nikolaos Fragakis, Κωνσταντίνος Κούσκουρας, et al.
Clinical Therapeutics (2024) Vol. 46, Iss. 11, pp. 841-850
Closed Access | Times Cited: 18
Mitochondrial Dynamics, Diabetes, and Cardiovascular Disease
Luis Miguel García-Peña, E. Dale Abel, Renata O. Pereira
Diabetes (2024) Vol. 73, Iss. 2, pp. 151-161
Open Access | Times Cited: 16
Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts
Masashi Mizuno, Atsushi Kuno, Toshiyuki Yano, et al.
Physiological Reports (2018) Vol. 6, Iss. 12, pp. e13741-e13741
Open Access | Times Cited: 153
Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
Charshawn Lahnwong, Nipon Chattipakorn, Nipon Chattipakorn
Cardiovascular Diabetology (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 151
A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats
Ayşegül Durak, Yusuf Olğar, Sinan Değirmenci, et al.
Cardiovascular Diabetology (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 142
How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial
Agnes Bosch, Christian Ott, Susanne Jung, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 99
Effect of hyperglycaemia and diabetes on acute myocardial ischaemia–reperfusion injury and cardioprotection by ischaemic conditioning protocols
Cláudia Penna, Ioanna Andreadou, Manuela Aragno, et al.
British Journal of Pharmacology (2020) Vol. 177, Iss. 23, pp. 5312-5335
Open Access | Times Cited: 90
Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts
Laween Uthman, Rianne Nederlof, Otto Eerbeek, et al.
Cardiovascular Research (2019) Vol. 115, Iss. 10, pp. 1533-1545
Open Access | Times Cited: 89
Targeting mitochondrial fusion and fission proteins for cardioprotection
Sauri Hernández‐Reséndiz, Fabrice Prunier, Henrique Girão, et al.
Journal of Cellular and Molecular Medicine (2020) Vol. 24, Iss. 12, pp. 6571-6585
Open Access | Times Cited: 85
Empagliflozin improves diabetic renal tubular injury by alleviating mitochondrial fission via AMPK/SP1/PGAM5 pathway
Xiangyang Liu, Chaofei Xu, Linxin Xu, et al.
Metabolism (2020) Vol. 111, pp. 154334-154334
Open Access | Times Cited: 82
SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models
Ioanna Andreadou, Robert M. Bell, Hans Erik Bøtker, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2020) Vol. 1866, Iss. 7, pp. 165770-165770
Open Access | Times Cited: 73
Effects of Sodium‐Glucose Linked Transporter 2 Inhibition With Ertugliflozin on Mitochondrial Function, Energetics, and Metabolic Gene Expression in the Presence and Absence of Diabetes Mellitus in Mice
Dominique Croteau, Ivan Luptak, Jordan M. Chambers, et al.
Journal of the American Heart Association (2021) Vol. 10, Iss. 13
Open Access | Times Cited: 58
A SGLT2 Inhibitor Dapagliflozin Alleviates Diabetic Cardiomyopathy by Suppressing High Glucose-Induced Oxidative Stress in vivo and in vitro
Yujie Xing, Biaohu Liu, Shujun Wan, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 58
Canagliflozin mitigates ferroptosis and ameliorates heart failure in rats with preserved ejection fraction
Sai Ma, Lili He, Guorui Zhang, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2022) Vol. 395, Iss. 8, pp. 945-962
Open Access | Times Cited: 51
Page 1 - Next Page

Scroll to top